Hormone Therapy and Breast Cancer Risk Following Prophylactic Surgery
Women with mutations in the BRCA1 or BRCA2 genes can reduce their risk for breast and ovarian cancer by having their ovaries removed, but then must decide whether to use hormone replacement therapy (HRT) for menopause symptoms triggered by that surgery. Fears that using HRT could compromise their reduced risk of breast cancer may now be diminished, because of results published early online in the Journal of Clinical Oncology.
Researchers at 13 cancer centers in North America and Europe identified a prospective cohort of 462 women with BRCA1 or BRCA2 gene mutations, 155 of whom had bilateral prophylactic oophorectomy (BPO). Compared with 307 mutation carriers who kept one or both ovaries, the BPO patients' breast cancer risk was reduced by 60 percent.
This reduced risk reflects what other studies have found, and explains why women with the mutations - as many as 90 percent of whom may develop breast or ovarian cancer if not treated - are advised by clinicians to undergo some form of BPO after completing childbearing. Read more
Guest Update by Dr. Anna Barker
Integrating Nanotechnology in Cancer Research
During the last few weeks we announced funding for three major components of the National Cancer Institute's (NCI's) Alliance for Nanotechnology in Cancer. These awards, which represent key milestones in NCI's Cancer Nanotechnology Plan, reflect the product of intense community planning and a long-term commitment to employ nanotechnology as a transformational force in cancer research.
All told, these components represent a comprehensive, national initiative designed to accelerate the application of nanotechnology's unique capabilities to cancer. We congratulate these investigator teams and their institutions for their vision and leadership. The recent announcements include funding for: